Image-based skin risk assessment
Analyzes visible skin concerns and provides risk indicators to help users decide whether further medical assessment may be needed.
Skinive
AI skin screening and mole monitoring for individuals and healthcare professionals
What is Skinive?
Skinive is an AI skin screening product that helps people assess visible skin concerns from smartphone images, track changes, and understand when professional care may be needed. It covers concerns such as moles, rashes, acne, and eczema.
The product range includes Skinive App for personal use, Skinive MD for healthcare professionals, and Skinive.Cloud for developers integrating skin analysis into other applications. Skinive describes its apps as CE-marked medical software developed by dermatologists. UV monitoring and sun-protection tools are built into the consumer app. Risk indicators support awareness and clinical workflows; they do not remove the need for examination of a new, changing, unusual, or concerning lesion.
What can Skinive do?
Guided image capture
Real-time AI camera guidance helps users capture clear, properly framed images for skin analysis.
Skin change tracking
Supports regular, structured skin self-checks and monitoring of visible changes over time.
Clinical mole mapping
3D full-body mole mapping helps clinicians document lesions and compare changes across assessments.
UV monitoring and sun protection
Shows current UV levels and forecasts, supports multiple locations, and provides exposure timers, SPF reminders, and guidance based on skin phototype and concerns.
Skin analysis API
Skinive.Cloud provides image quality checks, risk assessment, condition classification, and disease descriptions. Images rejected for poor quality are not charged.
Use Cases
“Review a new skin concern”
Individuals can assess a new spot, rash, or acne concern at home and use the risk insights to inform their next step.
“Document lesions in clinical practice”
Healthcare professionals can use Skinive MD to organize lesion documentation and support more consistent skin assessments.
“Plan outdoor activities”
Travelers and outdoor sports participants can compare UV conditions across locations and use personalized protection guidance when planning time outside.
“Add screening to a digital health service”
Developers can integrate Skinive.Cloud into telemedicine apps or EHR and EMR systems to support skin assessments, change tracking, and patient reports.
Frequently Asked Questions
Which devices support Skinive App?
Skinive App is available for iPhone and Android smartphones through the App Store and Google Play.
How should I act on a concerning result or lesion?
Any new, changing, unusual, or concerning lesion should be examined by a qualified healthcare professional. Skinive provides risk insights for screening and monitoring; do not treat an AI risk indication as a definitive diagnosis or as a reason to delay professional assessment.
Can developers connect users with a clinician?
Skinive.Cloud supports referral recommendations for online consultations or in-person appointments with a specialist. The booking workflow depends on the developer’s backend.
How is Skinive.Cloud priced?
Skinive.Cloud has a monthly usage-based pricing plan starting at €400 per month.
Quick Facts
- Category
- AI skin screening
- Product options
- Skinive App, Skinive MD, Skinive.Cloud
- Primary users
- Individuals, healthcare professionals, and application developers
- Developer delivery
- Cloud API
- Medical role
- Screening and monitoring support; concerning lesions need professional assessment
Skinive Traffic Analysis
Traffic data is for reference only.
- Monthly Visits
- 158.2K
- Global Rank
- #280,642
- User Bounce Rate
- 54.7%
- Avg. Visit Duration
- 00:28
- Pages per Visit
- 1.82
- Domain Rating
- 48
Traffic Trends
| Apr | 112066 |
|---|---|
| May | 129071 |
| Jun | 158155 |
Traffic Sources
- Direct: 47.5%
- Search: 46.6%
- Referral: 3.00%
- Social: 0.53%
- Mail: 0.89%
- Affiliate: 0.00%
Top Regions
- Russia: 17.8%
- Germany: 12.9%
- United States: 6.91%
- Italy: 4.36%
- Belarus: 4.18%
- Others: 53.9%
